Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06620172

CT-guided vs Fluoroscopy-guided Trigeminal Ganglion Radiofrequency Thermocoagulation for Idiopathic Trigeminal Neuralgia

The goal of this clinical trial is to compare the effectiveness and safety of CT-guided versus fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (TG-RFT) in treating idiopathic trigeminal neuralgia (TN) in adults aged 18 and older.

The main questions it aims to answer are:

* Does CT-guided TG-RFT provide better pain relief compared to fluoroscopy-guided TG-RFT? * What are the differences in medication consumption between the two methods? * What are the procedure-related adverse events for both methods?

Investigators will compare CT-guided TG-RFT to fluoroscopy-guided TG-RFT to see if one method is superior in treating idiopathic TN.

Participants will:

* Undergo either CT-guided or fluoroscopy-guided TG-RFT procedure * Be monitored post-procedure and followed up at 1, 3, and 6 months for pain relief, medication consumption, and adverse events.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zagazig University, Faculty of Medicine

Zagazig, Sharqia Province, 44519, Egypt

Location status: Recruiting

Location contact

Ahmed A Bessar, MD, PhD

CONTACT

[email protected]

+201000089595

About this study

This randomized controlled trial aims to compare the efficacy and safety of CT-guided versus fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (TG-RFT) in patients with idiopathic trigeminal neuralgia (TN). Idiopathic TN is characterized by severe, recurrent facial pain, and radiofrequency thermocoagulation is a common interventional treatment option.

Participants eligible for this study will be adults over 18 years old, diagnosed with idiopathic TN based on the International Headache Society criteria, experiencing pain for at least six months with a numeric rating scale (NRS) score greater than 6 despite medical treatment.

Exclusion criteria

include vascular compression of the trigeminal nerve by MRI, secondary causes such as multiple sclerosis, trigeminal autonomic cephalalgias, dental or temporomandibular joint pathologies, previous interventional procedures or surgery for TN, coagulopathy, use of antiaggregants and anticoagulants, cardiac pacemaker, renal-hepatic insufficiency, psychiatric illness, malignancy, or infection at the injection site or systemic infection.

Participants will be randomly assigned to either the CT-guided or fluoroscopy-guided RFT group using a computer-generated randomization list. Both procedures will be performed under aseptic conditions with appropriate monitoring and anesthesia. The CT-guided RFT will use real-time CT imaging for needle placement and monitoring, while the fluoroscopy-guided RFT will use fluoroscopic imaging.

The primary outcome measure is pain relief, assessed at 1-, 3-, and 6-months post-procedure using the Numeric Rating Scale (NRS) and Visual Analog Scale (VAS). Secondary outcomes include changes in medication consumption assessed by the Medication Quantification Scale III (MQS III) and the recording of procedure-related adverse events.

This study aims to provide valuable insights into the comparative effectiveness and safety of CT-guided versus fluoroscopy-guided TG-RFT in managing idiopathic TN, potentially guiding future clinical practice.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years
  • Idiopathic trigeminal neuralgia (TN) based on the International Headache Society criteria
  • Pain for at least six months and a NRS score greater than 6 despite medical treatment
  • Able to provide informed consent.
  • Agree to follow the study procedures and attend follow-up visits.

Exclusion criteria

  • Vascular compression of the trigeminal nerve by MRI and MRI angiography and the presence of secondary causes such as multiple sclerosis
  • Trigeminal autonomic cephalalgias accompanied by autonomic symptoms
  • Dental or temporomandibular joint pathologies
  • Previous interventional procedures or surgery for TN
  • Coagulopathy or use of antiaggregants and anticoagulants
  • Cardiac pacemaker
  • Renal-hepatic insufficiency
  • Diagnosis of psychiatric illness
  • Malignancy
  • Injection site or systemic infection
  • Current participation in another clinical trial that could interfere with the outcomes of this study.

Treatment and study plan

CT-guided Radiofrequency Thermocoagulation (RFT)

Procedure

Participants in this group will undergo CT-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure involves real-time CT imaging to guide the placement of the needle and monitor the process.

Fluoroscopy-guided Radiofrequency Thermocoagulation (RFT)

Procedure

Participants in this group will undergo fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure utilizes fluoroscopic imaging for needle placement and monitoring.

Primary outcomes

  1. Pain Relief - Numeric Rating Scale (NRS)

    Time frame: Baseline, immediately post-procedure, 1 month, 3 months, and 6 months post-procedure.

    The primary outcome measure will be the level of pain relief, as assessed by the Numeric Rating Scale (NRS), a 0-10 scale where 0 represents "no pain" and 10 represents "worst possible pain.". Pain levels will be recorded at baseline (pre-procedure), immediately post-procedure, and at 1-, 3-, and 6-months post-procedure.

  2. Pain Relief - Visual Analog Scale (VAS)

    Time frame: Baseline, immediately post-procedure, 1 month, 3 months, and 6 months post-procedure.

    Additionally, pain relief will be assessed by the Visual Analog Scale (VAS), a continuous scale ranging from 0 to 100 mm, where 0 represents "no pain" and 100 represents "worst possible pain." Pain levels will be recorded at the same time points: baseline, immediately post-procedure, and at 1-, 3-, and 6-months post-procedure.

Secondary outcomes

  1. Medication Consumption

    Time frame: 6 months post-procedure

    Changes in medication consumption will be assessed using the Medication Quantification Scale III (MQS III) at 6 months post-procedure. This measure will evaluate the impact of the interventions on the need for medications to manage trigeminal neuralgia.

  2. Procedure-related Adverse Events

    Time frame: Immediately post-procedure, 1 month, 3 months, and 6 months post-procedure

    Adverse events related to the interventions will be systematically recorded to evaluate the safety profile of CT-guided versus fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (TG-RFT). Adverse events will be monitored and recorded immediately post-procedure and during follow-up visits at 1, 3, and 6 months.

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmed A Bessar, M.D., PhD

CONTACT

[email protected]

01000089595

Sponsors and collaborators

Lead sponsor

Zagazig University

Other Gov

Registry information

Official study title

CT-guided vs Fluoroscopy-guided Trigeminal Ganglion Radiofrequency Thermocoagulation for Idiopathic Trigeminal Neuralgia: A Randomized Controlled Trial

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 1, 2024
Registry last updated
Nov 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.